FRED HUTCHINSON CANCER CENTER

Pharma industry sponsors dominate clinical cancer research, enrolling over eight times more patients than federally sponsored trials. This shift, which has dramatically increased over decades, benefits drug discovery but skews research priorities towards new drug approvals. Federally-funded trials address broader research questions and show higher demographic diversity. The influx of pharma-sponsored research raises concerns about potential bias in reported drug efficacy.

A SWOG study finds prostate cancer treatment increases 12-year risk of complications, with prostatectomy showing a 6.57 times greater risk and radiotherapy a 3.04 times greater risk compared to untreated participants. Specific risks include urinary, sexual complications, and bladder cancer. The study emphasizes patient education and inclusion of risk data in treatment guidelines.

The FDA's approval of Trodelvy for bladder cancer treatment has been withdrawn by Gilead Sciences due to TROPICS-04 study's failure to meet overall survival primary endpoint. This leaves fewer systemic therapy options for urothelial cancer patients, though Trodelvy remains approved for other cancer types. Patients currently on Trodelvy should consult their providers about continuing treatment.

Disis continues work on ADVac, an adipose-directed vaccine targeting obesity's role in breast cancer, funded by BCRF. Linden investigates FFNP PET/CT tracer to predict response to endocrine therapy with abemaciclib. King explores undiscovered mutations in inherited breast cancer, supported by BCRF funding.

A study in the Journal of Clinical Oncology reveals a growing reliance on industry for cancer clinical research in the U.S., with an 8.1 enrollment ratio for industry vs. federal sponsors from 2018 to 2022, up from 4.8 during 2008-2012.

Industry-sponsored cancer trials in the U.S. have seen an 8.1 enrollment ratio vs. federally sponsored trials from 2018-2022, up from 4.8 in 2008-2012. This shift highlights industry's growing role in cancer research.

Two studies in NEJM highlight SWOG Statistics and Data Management Center's role at Fred Hutch, challenging lymph node removal in bladder cancer and showing promise for nivolumab plus AVD chemotherapy in Hodgkin lymphoma. The SDMC, celebrating 40 years in Seattle, ensures study design rigor and data integrity, contributing to evidence-based care.

A study in the Journal of Clinical Oncology reveals a growing reliance on industry for cancer clinical research in the U.S., with an enrollment ratio of 8.1 for industry-sponsored vs. federally sponsored trials from 2018 to 2022.

Fred Hutchinson Cancer Center researchers, led by Dr. Julie McElrath, developed a new HIV vaccine formulation combining 3M-052-AF adjuvant with HIV Env trimers, inducing neutralizing antibodies in human trials. This marks a new vaccine platform needing optimization for broadly neutralizing antibodies against circulating HIV strains.

Colorectal cancer cases have significantly increased among younger age groups, leading to potential changes in screening guidelines and increased demand for clinical laboratory tests.